Evidence map›Paper›PMID 30998954›Full record

ArticlePharmacology, biochemistry, and behavior2019

The adrenergic receptor antagonist carvedilol interacts with serotonin 2A receptors both in vitro and in vivo.

Kevin Sean Murnane, Osman F Guner, J Phillip Bowen, Kalyn M Rambacher, Nader H Moniri, Tyler J Murphy, Cedrick Maceo Daphney, Aboagyewaah Oppong-Damoah, Kenner C Rice

Open access · greenAbstract read
In one paragraph

Article in Pharmacology, biochemistry, and behavior, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Biased signalingActa pharmaceutica Sinica. B · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kevin Sean MurnaneDepartment of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center, Atlanta, GA, USA. Electronic address: murnane_ks@mercer.edu.
Osman F GunerDepartment of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center, Atlanta, GA, USA.
J Phillip BowenDepartment of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center, Atlanta, GA, USA.
Kalyn M RambacherDepartment of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center, Atlanta, GA, USA.
Nader H MoniriDepartment of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center, Atlanta, GA, USA.
Tyler J MurphyDepartment of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center, Atlanta, GA, USA; Department of Biology, Oglethorpe University, Atlanta, GA, USA.
Cedrick Maceo DaphneyDepartment of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center, Atlanta, GA, USA.
Aboagyewaah Oppong-DamoahDepartment of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center, Atlanta, GA, USA.
Kenner C RiceSection on Drug Design and Synthesis, National Institute on Drug Abuse and Chemical Biology Research Branch, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.
Mercer University Health Sciences Center · USNational Institute on Drug Abuse · US

Funding

Receptor pharmacology and toxicology of second-generation pyrrolidine "bath salt" cathinonesR21DA040907 · NIDA · NORTHEASTERN UNIVERSITY · PI CANAL, CLINTON E, MURNANE, KEVIN SEAN · 2016 to 2017
$493k
A novel neuropeptide brain delivery system for epilepsyR21NS100512 · NINDS · MERCER UNIVERSITY MACON · PI ESCAYG, ANDREW P, MURNANE, KEVIN SEAN · 2016 to 2017
$440k
NIDA NIH HHS R21 DA040907NINDS NIH HHS R21 NS100512
6 · The paper itself

Abstract

There is increasing support for the potential clinical use of compounds that interact with serotonin 2A (5-HT

Indexed as

Adrenergic AntagonistsAmphetaminesAnimalsBehavior, AnimalBinding SitesCarvedilolComputational ChemistryDrug DiscoveryFluorobenzenesHEK293 CellsHumansLysergic Acid DiethylamideMaleMiceModels, AnimalModels, Molecular4-iodo-2,5-dimethoxyphenylisopropylamineAdrenergic AntagonistsAmphetaminesCarvedilolFluorobenzenesLysergic Acid DiethylamidePiperidinesReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor AntagonistsSerotonin Receptor Agonistsvolinanserin5-HT(2A)CarvedilolPharmacophorePsychedelic

Identifiers

PMID30998954
PMCPMC6570414
OpenAlexW2938297281

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.